BioSpace News Archive

enGene Inc., a clinical-stage biotechnology company pioneering non-viral gene therapies for local administration to mucosal tissues enabled by its proprietary DDX platform, today announced a poster presentation at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium being held from February 16th to 18th, 2023.

Eurofins Discovery, the leading provider of products and services to the drug discovery industry, announced its collaboration with Invasight, a Switzerland-based biotech developing cancer therapies.

Bio North Texas launched a video promoting growth and strength in the North Texas biomedical innovation ecosystem.

The FDA has approved the first Non-Covalent (Reversible) BTK (Bruton Tyrosine Kinase) inhibitor for the treatment of Relapsed or Refractory Mantle Cell Lymphoma in adult patients, based on clinical studies conducted with participation by Florida Cancer Specialists & Research Institute.

Eluminex Biosciences today announced the completion of clinical enrollment in Part A (N=5) of a two-part pivotal study (CLARITY) evaluating a novel EB-301 biosynthetic cornea being conducted in China.

KeifeRx announced the appointment of Garrett Vygantas, MD, MBA, to serve on the Company’s Board of Directors.

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux) today announced that Janux management will participate in a Novel Immuno-Oncology (IO) panel discussion at Cowen’s 43rd Annual Health Care Conference and be available for 1x1 meetings from March 6 to 8, 2023 in Boston.

The advent of immunotherapy has set a development foundation for modern cancer therapies, allowing emergence of novel modalities and targets shaping the future landscape for cancer treatment.

Profound Medical Corp. will announce its fourth quarter and full year 2022 financial results after market close on Tuesday, March 7, 2023.

Precision BioSciences, Inc. announced that, on February 9, 2023, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan.